NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024

MetaVia Inc.

Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.
95 of 109 randomized patients completed dosing across Part 1 (DA-1241 vs placebo) and Part 2 (DA-1241 + sitagliptin vs placebo).
Primary endpoint: change from baseline in ALT at Week 16; secondary endpoints include lipid and safety measures.
Topline data from both parts expected in December 2024; prior Phase 1 showed DA-1241 well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.